John Cox has joined Minovia therapeutics in February 2019 and brings over 25 years of experience in biopharmaceuticals.
Mr.Cox is currently the Chief Executive Officer of Repertoire Immune Medicines, and was formerly the CEO of Bioverativ, which he built and grew from a new venture with two drugs, Eloctate® and Alprolix® for the treatment of hemophilia A and B, into a global company with a significant pipeline, nearly 500 employees and over $1.1B in sales. In February 2018 Mr. Cox has led Bioverativ to a successful acquisition by Sanofi for $11.6B, creating $7B in shareholder value in 12 months.
Formerly, Mr. Cox held the position of Executive Vice President, Global Commercial & Technical Operations at Biogen, where he was a member of the leadership team and was globally responsible for all aspects of an $11 billion commercial operation, as well as technical development and all drug supply.
In his prior position at Biogen as Executive Vice President of Pharmaceutical Operations & Technology, he oversaw the company’s production facilities, supply chain operations, technical development, quality and engineering across the globe. He also had responsibility for the creation of the company’s biosimilar business, including its successful commercialization in Europe.
Before joining Biogen Idec in 2003, John held a number of senior operational roles with biotech contract manufacturer Covance/Diosynth, where he led teams engaged in technology transfer, validation and purification. Prior to that, he held positions of increasing responsibility in similar areas with vaccine-maker Wyeth Corp.
John holds an MBA from the University of Michigan, an MS in Cell Biology from California State University and a BS in Biology from Arizona State University.
Ph.D. in Biochemistry at The Hebrew University; Postdoctoral fellowship at the Weizmann Institute; Twenty years experience in mitochondrial research
General Manager of Soreq Nuclear Center, Israel, 1990-1998; Co-founded 6 successful hi-tech companies: Opal, X-Technologies, Kailight, Radiancy, Sonotron and Oplon; Serial entrepreneur and inventor
Ex-Deputy Head, Israel Institute for Biological Research; Ex-Executive, Siemens Israel; Serial angel investor in Israeli start up companies
Has vast experience in brokerage and investment banking as the former Chief Executive Officer and Partner at I. B. I. Investment Banking. Angel investor and member of the board of several companies